Clinical Case Reports (Dec 2019)

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin

  • Ritsuko Nakai,
  • Suguru Fukuhara,
  • Akiko Miyagi Maeshima,
  • Sung‐Won Kim,
  • Yuta Ito,
  • Shunsuke Hatta,
  • Tomotaka Suzuki,
  • Sayako Yuda,
  • Shinichi Makita,
  • Wataru Munakata,
  • Tatsuya Suzuki,
  • Dai Maruyama,
  • Koji Izutsu

DOI
https://doi.org/10.1002/ccr3.2543
Journal volume & issue
Vol. 7, no. 12
pp. 2500 – 2504

Abstract

Read online

Abstract This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.

Keywords